SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

CSF p-tau217 Normalization Requires Intact Synaptic Function and BBB Integrity (Neurodegeneration Floor Effect)

Target: NA - Patient stratification factor Composite Score: 0.515 Price: $0.50 Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
⚠ Missing Evidence⚠ Low Validation⚠ Orphaned Senate Quality Gates →
Quality Report Card click to collapse
C+
Composite: 0.515
Top 73% of 1374 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C+ Mech. Plausibility 15% 0.55 Top 67%
C Evidence Strength 15% 0.45 Top 76%
C+ Novelty 12% 0.58 Top 81%
C Feasibility 12% 0.48 Top 68%
C+ Impact 12% 0.52 Top 78%
D Druggability 10% 0.30 Top 89%
B Safety Profile 8% 0.62 Top 33%
B+ Competition 6% 0.70 Top 39%
C+ Data Availability 5% 0.50 Top 68%
C Reproducibility 5% 0.45 Top 78%
Evidence
2 supporting | 2 opposing
Citation quality: 0%
Debates
0 sessions
No debates yet
Convergence
0.00 F 30 related hypothesis share this target

Description

In advanced neurodegeneration, p-tau217 may no longer reflect ongoing pathology due to loss of viable neurons capable of producing tau. Patients with severe atrophy may show spurious p-tau217 normalization due to floor effects, making it unreliable as a stopping rule. However, no threshold defines 'severe' neurodegeneration for this purpose, and the relationship between structural atrophy and neuronal p-tau217 production capacity is not established. The hypothesis identifies an important confound but lacks operational criteria.

No AI visual card yet

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.55 (15%) Evidence 0.45 (15%) Novelty 0.58 (12%) Feasibility 0.48 (12%) Impact 0.52 (12%) Druggability 0.30 (10%) Safety 0.62 (8%) Competition 0.70 (6%) Data Avail. 0.50 (5%) Reproducible 0.45 (5%) KG Connect 0.50 (8%) 0.515 composite
4 citations 4 with PMID Validation: 0% 2 supporting / 2 opposing
✓ For (2)
No supporting evidence
No opposing evidence
(2) Against ✗
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
2
MECH 2CLIN 2GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Neurofilament light trajectories diverge based on …SupportingMECH----PMID:37616244-
Synaptic loss assessed by SV2A PET predicts biomar…SupportingCLIN----PMID:34152996-
No published study explicitly tests p-tau217 valid…OpposingMECH----PMID:NA-
Advanced AD patients were largely excluded from TR…OpposingCLIN----PMID:NA-
Legacy Card View — expandable citation cards

✓ Supporting Evidence 2

Neurofilament light trajectories diverge based on baseline atrophy in donanemab trials
PMID:37616244
Synaptic loss assessed by SV2A PET predicts biomarker responsiveness
PMID:34152996

✗ Opposing Evidence 2

No published study explicitly tests p-tau217 validity across neurodegeneration severity strata
PMID:NA
Advanced AD patients were largely excluded from TRAILBLAZER-ALZ
PMID:NA
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.

Price History

No price history recorded yet

7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (3)

Dolly at 25… is she '… still goin' strong?'.
Reproduction (Cambridge, England) (2022) · PMID:34152996
No extracted figures yet
Genomic characterization of a novel, widely distributed Mycoplasma species "Candidatus Mycoplasma mahonii" associated with the brittlestar Gorgonocephalus chilensis.
PloS one (2023) · PMID:37616244
No extracted figures yet
Paper:NA
No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration
Score: 0.990 | neurodegeneration
TREM2-Dependent Microglial Senescence Transition
Score: 0.950 | neurodegeneration
PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction
Score: 0.941 | neurodegeneration
Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction
Score: 0.933 | neurodegeneration
CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal
Score: 0.921 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 NA — Search for structure Click to search RCSB PDB
🔍 Searching RCSB PDB for NA structures...
Querying Protein Data Bank API

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

← Back to Exchange | Dashboard